ReviewMolecular therapy : the journal of the American Society of Gene Therapy2022
Global challenges in preparedness and response to epidemic infectious diseases.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Integrating mathematical modelling and artificial intelligence to combat emerging viral syndemics: A systematic review.New microbes and new infections · 2026Review
- Development and validation of a national questionnaire assessing knowledge, attitudes, and practices on neglected tropical diseases among italian medical trainees.PLoS neglected tropical diseases · 2026Article
- Paleopathology Meets Public Health: Deep-Time Syndemics and the Ecology of Emerging Infections.Pathogens (Basel, Switzerland) · 2026Review
- Early Detection and Surveillance of Infectious Disease Outbreaks in Nigeria : Integrating Nigerian Pidgin English (NPE) into the EPIWATCHJournal of medical systems · 2026Article
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Evaluating a Research Training Program in Environmental Health and Noncommunicable Diseases in Georgia.International journal of environmental research and public health · 2025Article
- PEARLES challenges and solutions to the implementation of clinical research responses to epidemics and pandemics: a scoping review.EClinicalMedicine · 2025Review
- Article
- A time series study of the association between extreme temperature and ozone on varicella incidence.Scientific reports · 2024Article
- An mRNA technology transfer programme and economic sustainability in health care.Bulletin of the World Health Organization · 2024Article
- Financing for pandemic preparedness and response measures: a systematic scoping review.Bulletin of the World Health Organization · 2024Article
- TV medical dramas: assessing the portrayal of public health in primetime.Frontiers in public health · 2024Article
- The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases.PLOS global public health · 2024Article
- Review
- Stopping epidemics when and where they occur.Lancet (London, England) · 2023Article
- The outbreak of Ebola virus disease in 2022: A spotlight on a re-emerging global health menace.Narra J · 2022Review
- Amplified effect of social vulnerability on health inequality regarding COVID-19 mortality in the USA: the mediating role of vaccination allocation.BMC public health · 2022Article
- Molecular therapies and vaccines face the challenges of emerging infectious diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Lessons drawn from successes and failures with coronavirus disease 2019 (COVID-19) and Ebola virus disease (EVD) should help shaping a robust health innovation system for infectious disease epidemics. Epidemic response research and development (R&D) can be mobilized quickly for public health priorities and yield medicinal products within months. However, to resolve epidemics, technological advances must be equitably accessible and deployed, and these examples expose the limitations of a supply-driven, fragmented R&D ecosystem relying primarily on the private sector to deliver health products. Efficient epidemic response requires a coordinated public health-focused, end-to-end R&D ecosystem for the development, registration, availability, and use of pharmaceutical products. Because pivotal clinical trials can only be conducted during outbreaks, significant preparation must be done beforehand: strengthening clinical research capacity and developing pre-positioned trial protocols and clinical characterization protocols, as well as conducting discovery and pre-clinical research, manufacturing, and early clinical testing of candidate products. This will allow for speedy execution of clinical research early into an outbreak and delivering products within a short time. Effective interventions should be adopted and deployed ensuring equitable access during the ongoing outbreak. Measures to make products available where and when needed must be integrated throughout the R&D value chain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.